SCHEMBL20985606

SCHEMBL20985606

Cn1nc(Cl)c2ccc(Br)cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 1/20 0.41
CDK5 Q00535 1/20 0.41
TYRO3 Q06418 1/20 0.41
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
ESR1 P03372 1/20 0.36
CHEK1 O14757 1/20 0.36
MAPK8 P45983 1/20 0.35
PTGES O14684 1/20 0.35
BACE1 P56817 1/20 0.34
NPM1 P06748 1/20 0.34
ALK Q9UM73 1/20 0.34
MIF P14174 1/20 0.33
PDE4B Q07343 1/20 0.33
EGLN1 Q9GZT9 2/20 0.33
PARG Q86W56 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
AXL P30530 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23474004 0.79 ADORA2A (0.44) ADORA2AADORA2BESR1PARGMEN1
SCHEMBL30032217 0.79 ADORA2A (0.59) PDGFRACDK5TYRO3ADORA2AADORA2B
SCHEMBL2144982 0.79 ADORA2A (0.59) PDGFRACDK5TYRO3ADORA2AADORA2B
SCHEMBL24406069 0.79 PDGFRA (0.38) PDGFRACDK5TYRO3CHEK1PTGES
SCHEMBL31758562 0.78 PDGFRA (0.41) PDGFRACDK5TYRO3ADORA2AADORA2B
SCHEMBL10112108 0.78 PDGFRA (0.44) PDGFRACDK5TYRO3ADORA2AADORA2B
SCHEMBL15068967 0.78 DDB1 (0.47) ADORA2AADORA2BESR1BACE1PARG
SCHEMBL29946979 0.78 PDGFRA (0.59) PDGFRACDK5TYRO3ADORA2AADORA2B
SCHEMBL16132897 0.78 PDGFRA (0.41) PDGFRACDK5TYRO3ADORA2AADORA2B
SCHEMBL30112337 0.78 PDGFRA (0.41) PDGFRACDK5TYRO3ADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11802120-B2 Fused cyclic urea derivatives as CRHR2 antagonist RAQUALIA PHARMA INC. (JP) 2023-10-31 US disclosed
US-20210078975-A1 FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST RAQUALIA PHARMA INC. (JP) 2021-03-18 US disclosed
US-20190151312-A1 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. 2019-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190151312-A1 HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES HPSE, GAA, MAN2B1 PDGFRA 1791/4885CDK5 2751/4885TYRO3 2385/4885
US-20210078975-A1 FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST CRHR2, CRHR1, CRH PDGFRA 4762/4885CDK5 256/4885TYRO3 4773/4885
US-11802120-B2 Fused cyclic urea derivatives as CRHR2 antagonist CRHR2, CRHR1, CRH PDGFRA 4762/4885CDK5 256/4885TYRO3 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.